About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Metabolomic Analysis of Systemic Sclerosis | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDNCT02298777

Metabolomic Analysis of Systemic Sclerosis

Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years. The primary purpose is...

Lead sponsor: University Hospital, Strasbourg, France•4 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospital, Strasbourg, France

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Group 1 (scleroderma) : Patients with ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)
•Group 2 (UCDT) : Patients with criteria proposed by Mosca et al. (1998)
•Group 3 (Raynaud) : Patients with primary and isolated Raynaud disease
•Group 4 (vascular disease) : Patients with type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke
•Group 5 (healthy control) : healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)

Exclusion Criteria

•Group 1 (scleroderma) : Patients not fulfilling ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001), or with another auto-immune disease
•Group 2 (UCDT) : Patients not fulfilling criteria proposed by Mosca et al. (1998)
•Group 3 (Raynaud) : Patients with no Raynaud disease
•Group 4 (vascular disease) : Patients with no vascular disease
•Group 5 (healthy control) : Patients with sign of connective tissue disease, Raynaud, or vascular disease)

Related studies

Rheumatology Patient Registry and Biorepository

NCT04402086 · Rheumatic Diseases, Adult Onset Still Disease, and more

Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma

NCT07292961 · Scleroderma, Scleroderma, Localized, and more

Multi-modal Quantitative Imaging of the Skin

NCT06989216 · Skin Cancer, Skin Diseases, and more

TERMINATEDPhase 2/3

Exparel as a Nerve Block for Severe Hand Pain

NCT02374320 · CREST Syndrome, Peripheral Vascular Disease, and more

UNKNOWNPhase 2/3

COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases

NCT05236491 · Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 8, 2025Terms

Trial snapshot

StatusTERMINATED

Phase—

Enrollment121

Start dateDec 2014

Last updatedAug 8, 2025

Condition

Scleroderma (Limited and Diffuse)Undifferentiated Connective Tissue Disease Raynaud Disease Vascular Disease Healthy Control Subjects

Locations shown

CHU

Dijon

Hôpitaux privés de Metz

Metz

CHU

Reims

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 8, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions